---
layout: post
title: "Dual Labeling for Fully Approved and Conditionally Approved New Animal Drugs With a New World Screwworm-Related Indication; Guidance for Industry; Availability"
date: 2026-02-04 21:45:58 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-19565
original_published: 2025-10-16 00:00:00 +0000
significance: 8.00
---

# Dual Labeling for Fully Approved and Conditionally Approved New Animal Drugs With a New World Screwworm-Related Indication; Guidance for Industry; Availability

**Published:** February 04, 2026 21:45 UTC
**Source:** Federal Register
**Original Published:** October 16, 2025 00:00 UTC
**Document Number:** 2025-19565

## Summary

The Food and Drug Administration (FDA, the Agency, or we) is announcing the availability of a final guidance for industry (GFI) #299 entitled "Dual Labeling for Fully Approved and Conditionally Approved New Animal Drugs With a New World Screwworm-Related Indication." This guidance is intended to inform new animal drug sponsors that dual labeling of a new animal drug product may include an intended use that is fully approved under section 512(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and an intended use that is conditionally approved under section 571 of the FD&C Act where the claim to be added to the existing product labeling is intended to treat or prevent New World screwworm myiasis.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/10/16/2025-19565/dual-labeling-for-fully-approved-and-conditionally-approved-new-animal-drugs-with-a-new-world)
- API: https://www.federalregister.gov/api/v1/documents/2025-19565

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
